Public Employees Retirement System of Ohio Acquires New Stake in Halozyme Therapeutics, Inc. $HALO

Public Employees Retirement System of Ohio bought a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 37,037 shares of the biopharmaceutical company’s stock, valued at approximately $2,899,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of HALO. Redwood Investment Management LLC bought a new stake in shares of Halozyme Therapeutics in the second quarter valued at about $2,203,000. Corient Private Wealth LP bought a new position in shares of Halozyme Therapeutics during the second quarter worth about $14,671,000. Panoramic Capital LLC acquired a new stake in Halozyme Therapeutics in the 2nd quarter valued at approximately $9,112,000. Bank of America Corp DE acquired a new stake in Halozyme Therapeutics in the 2nd quarter valued at approximately $214,504,000. Finally, Freestone Grove Partners LP bought a new stake in Halozyme Therapeutics in the 2nd quarter valued at approximately $1,424,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. UBS Group reaffirmed a “buy” rating and set a $90.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Finally, Leerink Partners upgraded shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $83.00 to $110.00 in a research note on Friday, August 7th. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $91.20.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $110.19 on Friday. The stock has a market cap of $12.51 billion, a P/E ratio of 32.89, a P/E/G ratio of 0.43 and a beta of 0.88. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. The company has a fifty day moving average price of $90.76 and a two-hundred day moving average price of $75.82. Halozyme Therapeutics, Inc. has a one year low of $61.22 and a one year high of $111.15.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The company had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. During the same period in the previous year, the business earned $1.54 EPS. Halozyme Therapeutics’s revenue for the quarter was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, equities analysts predict that Halozyme Therapeutics, Inc. will post 7.98 EPS for the current year.

Trending Headlines about Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Analyst maintains Buy rating: HC Wainwright reaffirmed its Buy rating on Halozyme Therapeutics, supporting the bullish view of the company’s growth outlook. HC Wainwright Reaffirms Buy Rating for Halozyme Therapeutics
• Positive Sentiment: Higher earnings expectations: Zacks Research raised its FY2026 EPS forecast to $8.24 from $7.56, above the provided consensus estimate of $7.98. It also lifted forecasts for several 2027 and 2028 quarters, including FY2027 EPS to $9.01 from $8.96, indicating improving expectations for Halozyme’s earnings trajectory. Zacks Research Issues Positive Forecast for HALO Earnings
• Positive Sentiment: Value and growth appeal: Zacks included HALO among four high-growth stocks with discounted PEG ratios for 2026. The designation may attract investors seeking earnings growth at a relatively reasonable valuation, particularly after Halozyme’s strong recent results and revenue growth. 4 High-Growth GARP Stocks With Discounted PEG Ratios for 2026
• Neutral Sentiment: Momentum has been strong: HALO recently hit a new one-year high, reflecting investor enthusiasm and continued upward momentum. However, trading near that high can also increase sensitivity to profit-taking and valuation concerns. Halozyme Therapeutics Hits New 1-Year High
• Negative Sentiment: One longer-term estimate was trimmed: Zacks lowered its FY2028 EPS forecast to $10.06 from $10.21, a minor reduction that partially offsets the otherwise positive revisions.

Insider Buying and Selling at Halozyme Therapeutics

In related news, Director Mahesh Krishnan sold 7,304 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the transaction, the director directly owned 14,462 shares of the company’s stock, valued at approximately $1,084,650. The trade was a 33.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the sale, the director directly owned 40,418 shares of the company’s stock, valued at $4,154,970.40. This represents a 3.87% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 32,478 shares of company stock worth $3,076,604 over the last 90 days. Company insiders own 2.50% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.